Lunai Bioworks signs collaboration agreement with BrainStorm Therapeutics on Parkinson’s disease research

• Lunai Bioworks signed a Master Collaboration Agreement with BrainStorm Therapeutics focused on precision Parkinson’s disease drug development.
• First collaboration data readout targeted for the first half of 2027.
• BioSymetrics’ Contingent AI platform will stratify Parkinson’s patients, prioritize biomarkers, identify therapeutic targets.
• BrainStorm will test hypotheses in patient-derived midbrain organoids, generate translational evidence to support partner-ready programs.
• Strategy targets near-term trial design support, medium-term biomarker panels, longer-term therapeutic programs for pharma partnering.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608041528PR_NEWS_USPR_____LA19226) on August 04, 2026, and is solely responsible for the information contained therein.